 NEW HAVEN, Conn., June 07, 2022 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. Nasdaq: BTAI, a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences. Dr. Mehta will discuss the Companys neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. He will also discuss the Companys commercial and launch readiness plans for IGALMITM dexmedetomidine sublingual film. 